The FDA cleared Regeneron’s gene therapy Otarmeni for a rare inherited hearing loss condition, marking the first gene therapy greenlit under the agency’s National Priority Voucher program. Regeneron said eligible patients will receive the therapy at no cost in the U.S. Regulators also linked the clearance to early clinical results showing modest hearing gains in a rare patient population where hearing restoration options are limited. The National Priority Voucher framework is intended to accelerate certain high-impact therapies through a streamlined path tied to priority review criteria. For the gene therapy market, the decision adds momentum to voucher-backed programs and intensifies competition for next-generation hearing loss assets targeting similar patient segments. Companies developing audiology gene therapies will now look to Otarmeni’s pricing-and-access model as a benchmark for payer and stakeholder expectations.